COMP <GO>
SMMT vs BBIO // FORWARD P/E MULTIPLE
Summit Therapeutics Inc. (NASDAQ) VS. BridgeBio Pharma Inc. (NASDAQ) • 15-METRIC TALLY: SMMT 5
— BBIO 5
▲ FORWARD P/E MULTIPLE LEADER: BBIO
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
forward-pe
34.0x
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
forward-pe
33.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SMMT VS. BBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SMMT | BBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 95.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.50% | -3.23% | +0.73 | SMMT | /fcf-yield <GO> |
| Operating Margin | -36.30% | -60.00% | +23.70 | SMMT | /operating-margins <GO> |
| Net Profit Margin | -29.80% | -60.00% | +30.20 | SMMT | /net-margins <GO> |
| Revenue Growth (YoY) | 11.00% | 126.30% | -115.30 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | SMMT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 63.9 | -13.40 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.00 | -0.03 | BBIO | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 34.0x | 33.0x | +1.00 | BBIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.82B | $14.60B | -$1.78B | BBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SMMT REV | BBIO REV | SMMT GROSS % | BBIO GROSS % | SMMT FCF | BBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.57B | $502.1M | — | 95.8% | -$323.6M | -$447.0M |
| FY 2024 | $632.8M | $221.9M | — | 98.3% | -$142.2M | -$521.7M |
| FY 2023 | $1.71B | $9.3M | — | — | -$76.8M | -$528.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SMMT // BETA 0.97
BBIO // BETA 1.00